APOC-III-L-Rx + Placebo Comparator
Phase 1Completed 0 watching 0 views this week💤 Quiet
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Elevated Triglycerides (TG)
Conditions
Elevated Triglycerides (TG)
Trial Timeline
Sep 1, 2016 → Apr 30, 2018
NCT ID
NCT02900027About APOC-III-L-Rx + Placebo Comparator
APOC-III-L-Rx + Placebo Comparator is a phase 1 stage product being developed by Ionis Pharmaceuticals for Elevated Triglycerides (TG). The current trial status is completed. This product is registered under clinical trial identifier NCT02900027. Target conditions include Elevated Triglycerides (TG).
Hype Score Breakdown
Clinical
10
Activity
5
Company
7
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02900027 | Phase 1 | Completed |
Competing Products
12 competing products in Elevated Triglycerides (TG)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Muvalaplin + Placebo | Eli Lilly | Phase 3 | 77 |
| Baricitinib | Eli Lilly | Pre-clinical | 23 |
| Rosuvastatin | AstraZeneca | Phase 3 | 77 |
| TQJ230 + Placebo | Novartis | Phase 3 | 77 |
| LIK066 + Placebo | Novartis | Phase 2 | 52 |
| Olpasiran | Amgen | Phase 1 | 32 |
| Maridebart cafraglutide + Placebo | Amgen | Phase 2 | 51 |
| Ivabradine | Amgen | Phase 3 | 76 |
| ALN-PCS02 + Sterile Normal Saline (0.9% NaCl) | Alnylam Pharmaceuticals | Phase 1 | 30 |
| ISIS-APO(a)Rx + Placebo | Ionis Pharmaceuticals | Phase 2 | 49 |
| ISIS 681257 + Placebo | Ionis Pharmaceuticals | Phase 2 | 49 |
| IONIS-APO(a)-LRx + Sterile Normal Saline (0.9% NaCl) | Ionis Pharmaceuticals | Phase 1 | 30 |